跳转至内容
Merck
CN

主要文件

查看所有文档

O003

β-Funaltrexamine hydrochloride

Opioid receptor antagonist, solid

别名:

β-FNA hydrochloride, (E)-4-[[(5α,6β)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]amino]-4-oxo-2-butenoic acid methyl ester hydrochloride

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C25H30N2O6 · HCl
化学文摘社编号:
72786-10-8
分子量:
490.98
UNSPSC Code:
12352116
PubChem Substance ID:
24897921
NACRES:
NA.77
MDL number:
MFCD10565941
Form:
solid
Quality level:
100
Storage condition:
desiccated
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

β-Funaltrexamine hydrochloride, solid

form

solid

Quality Level

100

drug control

regulated under CDSA - not available from Sigma-Aldrich Canada

storage condition

desiccated

color

white

solubility

H2O: 7.5 mg/mL (aqueous solutions should be promptly used), methanol: 7.6 mg/mL (do not store in ethanolic solution; methanolic solutions may be stored for several weeks at 4 °C)

storage temp.

−20°C

SMILES string

Cl.COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5OC1[C@]2(CCN3CC6CC6)c45

InChI

1S/C25H30N2O6.ClH/c1-32-20(30)7-6-19(29)26-16-8-9-25(31)18-12-15-4-5-17(28)22-21(15)24(25,23(16)33-22)10-11-27(18)13-14-2-3-14;/h4-7,14,16,18,23,28,31H,2-3,8-13H2,1H3,(H,26,29);1H/b7-6+;/t16-,18-,23+,24+,25-;/m1./s1

InChI key

BIPHUOBUKMPSQR-NQGXHZAGSA-N

Biochem/physiol Actions

Selective irreversible μ opioid receptor antagonist that is also a κ opioid receptor agonist.

Features and Benefits

This compound is featured on the Opioid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000211518
0000211518
0000100179
0000081146
054M4613V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

实验方案

LC/MS Analysis of Opioid Glucuronide Metabolites in Urine on Ascentis® Express F5 after Solid Phase Extraction (SPE) using Supel™-Select HLB

LC/MS Analysis of Opioid Glucuronide Metabolites in Urine on Ascentis® Express F5 after Solid Phase Extraction (SPE) using Supel™-Select HLB

Thomas J Martin et al.
Anesthesiology, 114(3), 633-642 (2011-02-05)
Neuropathic pain alters opioid self-administration in rats. The brain regions altered in the presence of neuropathic pain mediating these differences have not been identified, but likely involve ascending pain pathways interacting with the limbic system. The amygdala is a brain
Sarah A Nickolls et al.
Journal of biomolecular screening, 16(7), 706-716 (2011-05-10)
The correct interpretation of data is fundamental to the study of G-protein-coupled receptor pharmacology. Often, new assay technologies are assimilated into the drug discovery environment without full consideration of the data generated. In this study, the authors look at µ-opioid
R B Rothman et al.
Synapse (New York, N.Y.), 8(2), 86-99 (1991-06-01)
beta-Funaltrexamine (beta-FNA) is an alkylating derivative of naltrexone. In addition to acting as an irreversible inhibitor of mu-receptor-mediated physiological effects, intracerebroventricular (i.c.v.) administration of beta-FNA to rat attenuates the ability of selective delta receptor antagonists and naloxone to reverse delta
查看所有相关文献

全球贸易项目编号

货号GTIN
O003-10MG04061832557649
O003-2MG04061834212454